Year : 2017 | Volume
: 1 | Issue : 2 | Page : 43--47
Recurrent aphthous stomatitis
M Namrata, R Abilasha
Department of Oral Pathology, Saveetha Dental College, Saveetha Dental College, Chennai, Tamil Nadu, India
Department of Oral Pathology, Saveetha Dental College, Saveetha Dental College, Chennai, Tamil Nadu
Recurrent aphthous stomatitis (RAS) is commonly known as mouth ulcer. RAS is a very common disease of the mouth. Hence, it is important for dental clinicians to know about the clinical features, causes, diagnostic techniques, and the treatment and management of RAS. Clinically, RAS is seen in three forms minor RAS, major RAS, herpetiform RAS, and in HIV patients, the fourth form is seen. Considerable amount of research has been done to elucidate the causes of RAS; local factors, systemic factors, genetic factors, microbial factors, immunologic factors, etc., but to date, no principal etiology has been discovered. There are three lines of treatment suggested for the treatment of RAS but the treatment generally given is symptomatic. This review gives an up-to-date view of the disease.
|How to cite this article:|
Namrata M, Abilasha R. Recurrent aphthous stomatitis.Int J Orofac Biol 2017;1:43-47
|How to cite this URL:|
Namrata M, Abilasha R. Recurrent aphthous stomatitis. Int J Orofac Biol [serial online] 2017 [cited 2018 Sep 22 ];1:43-47
Available from: http://www.ijofb.org/text.asp?2017/1/2/43/223818
The Greek term “aphthae” was initially used in relation to disorders of the mouth and is credited to Hippocrates (460–370 BC). Today, recurrent aphthous ulceration, or recurrent aphthous stomatitis (RAS), is recognized as the most common oral mucosal disease known to human beings. Epidemiological studies indicate that the prevalence of RAS is between 2% and 50% in the general population; most estimates fall between 5% and 25%,,, The peak age of onset for RAS is between 10 and 19 years., This may continue throughout their life and this leading to RAS.
Earlier studies by Ship et al. found that RAS had a definite tendency to occur along family lines and that the probability of a sibling developing RAS was influenced by the parents' RAS status. A high correlation of RAS has been detected in identical twins but not in nonidentical twins. More recent investigations  have detected associations between RAS and specific HLA subtypes, which indicates that RAS in certain persons may have a genetic basis.
The trauma can include anesthetic injection, sharp food causing intraoral trauma, traumatic tooth brushing, and trauma during dental procedure. Many patients with RAS do not develop lesions after trauma though, and edentulous patients are unlikely to have lesions beneath dentures. Polanska et al. suggested the role of neutrophil elastase in the process of posttraumatic formation of aphthous ulcer. On the other hand, based on the epidemiological observations, most of the researchers indicate the lower incidence of RAS in smokers in comparison to nonsmoking patients, with a correlation with habit duration and severity;, that could be explained by a higher level of oral mucosa keratinization in response to smoking, which makes it less prone to injury and irritation.,
It has been suggested that oral streptococci and several viruses may play an etiologic role in RAS, but overall, the results are inconclusive. In general, herpes simplex, varicella zoster, and Epstein–Barr viruses have not been directly isolated from RAS lesions. A recent study  demonstrated an association between RAS recurrences and reactivation of varicella zoster virus and cytomegalovirus infection. Pedersen  has suggested that the systemic and local cellular immunosuppression associated with RAS is consistent with a viral reactivation or is a result of a latent viral infection of oral mucosa. Nevertheless, further research is needed to definitively establish a viral cause.
RAS has been observed in several systemic disorders, including Bechet's disease, cyclic neutropenia, mouth and genital ulcers with inflamed cartilage syndrome, nutritional deficiencies with and without underlying gastrointestinal disorders, and immunocompromised conditions including HIV infection. Aphthous-like ulcers have been detected in patients with Crohn's disease and ulcerative colitis and other small bowel changes. The lesions in these patients may occur at any time during the course of the disease, can be present before any intestinal symptoms occur, and may occur more frequently when the intestinal problems become active. These ulcers are histologically similar to the intestinal lesions of the disease. No associations have been established between RAS and the premenstrual period, pregnancy, or menopause. Furthermore, no properly designed study has shown a therapeutic effect of ovarian hormones on RAS, which suggests that the lesions of RAS are not caused by changes in female hormones.
Deficiencies in iron, folic acid, zinc, and vitamins B1, B2, B6, B12 have been detected in patients with RAS. Hematological deficiencies in patients with RAS  may be related to abnormalities of the small intestine, including celiac disease (gluten-sensitive enteropathy), although these patients may not always have symptoms of bowel disease. Volkovetal et al. observed positive effects of the oral vitamin B12 supplementation in RAS patients regardless of the initial serum levels of this microelement.
Food sensitivities and allergies to other substances can also cause ulcers in hematologically normal patients with recurrent lesions. According to some researchers, also the exposition to some food ingredients, for example, chocolate, gluten, cow milk, preservatives, nuts, and food coloring agents may induce the pro-inflammatory cascade in RAS.,
Some studies , have associated stress with RAS; however, a more recent investigation  revealed no association between psychological life stress and recurrences of RAS. Nevertheless, the literature continues to report that stress may play a role in precipitating RAS, and severe emotional or environmental stress should be contemplated in the clinical assessment of RAS. According to some authors, it rather triggers the onset of the episode than influences its duration.,
RAS may have primary immunologic abnormalities that result in altered immunoregulatory balances. For example, there are increases in antibody-dependent cell cytotoxicity , and greater levels of serum immunoglobulins  in patients with RAS. Lymphocytes from patients with severe RAS demonstrate increased numbers of T-helper/inducer cells, decreased numbers of T-suppressor/inducer cells, and depressed responses to mitogens. Activated T-lymphocytes aggregate in the periphery of RAS lesions confirming the hypothesis that RAS represents an activated cell-mediated immune response. Immunohistochemical studies of lymphocyte subsets in aphthous ulcers of HIV-seronegative patients  and HIV-seropositive patients  have yielded similar findings, which strongly indicates that these ulcers represent a cell-mediated immunologic dysfunction in which infiltrating T-lymphocytes play a primary role.
It is classified into three types based on clinical manifestation – minor RAS, major RAS, and herpetiform RAS.,,
Major Recurrent Aphthous Stomatitis
Major RAS is occasionally referred to as Sutton's disease or periadenitis mucosa necrotica recurrens  and is less common (approximately 10% to 15% of all RAS) yet more severe than minor RAS. Major RAS lesions are similar in appearance to those of minor RAS; however, they are larger than 10 mm in diameter, are deeper, often scar, and can last for weeks to months. MaRAS usually has its onset after puberty and is chronic, persisting for up to 20 or more years. They occur on movable nonkeratinizing oral surfaces (labial and buccal mucosa and floor of the mouth), but the ulcer borders may extend onto keratinized surfaces.
Minor Recurrent Aphthous Stomatitis
Minor RAS have been reported to cause 70%–87% of all forms of RAS, with more than 17% of the population being reported to have minor RAS. Minor RAS manifests as recurrent, round, clearly defined, small, painful ulcers with shallow necrotic centers, raised margins, and erythematous halos. These lesions are 5–10 mm in diameter and have a gray-white pseudomembrane , These lesions heal within 10–14 days without scarring. The most common location is on nonkeratinized oral mucosa (the labial and buccal mucosa and floor of the mouth). Lesions appear as single or multiple ulcers but can be distinguished from other mucocutaneous diseases based on their history, location, healthy appearance of adjacent tissues, and the lack of distinguishing systemic features.
Herpetiform Recurrent Aphthous Stomatitis
The least common form of RAS is herpetiform aphthous ulcers, which afflict 5% to 10% of patients with RAS. It occurs more frequently in females, and onset is often in adulthood. Multiple small clusters of pinpoint ulcers characterize this rare form of RAS, and they occur throughout the oral cavity. They tend to be small (2–3 mm) and numerous (ranging from 10 to 100 ulcers) but can become confluent to produce larger, plaque-form, irregular lesions. Lesions last 7–30 days and have the potential to scar. Although these lesions are herpes like or herpetic form in nature, herpes simplex virus (HSV) cannot be cultured from these lesion.
Hiv-Associated Recurrent Aphthous Stomatitis
Large aphthous-like ulceration are seen associated with HIV-positive patients with the prevalence of approximately 2%–3%. Frequently major RAS is found in patients infected with human immunodeficiency virus (HIV),,, perhaps because of the amplification of local immune imbalance secondary to HIV disease.
Diagnosis Serologic, Chemical, Hematologic Finding
Full hematologic screening of patients with RAS has been proposed to reveal deficiency states of serum ferritin, iron, folate, and Vitamin B., Deficient levels of serum ferritin or iron are the most common findings occurring in 11% to 36% of patients with RAS.,,, Hematologic screening of children with RAS is also recommended because it has been reported that 21% of patients have some type of hematologic abnormality, most notably latent iron deficiency without anemia.
A histopathologic specimen is rarely required for the diagnosis of RAS because of the nonspecific nature of the ulcer. However, if another oral mucocutaneous condition is suspected, then a biopsy may be necessary. In the preulcerative phase, there is a mild infiltrate of T4 helper-inducer lymphocytes, which becomes an infiltrate of T8 cytotoxic-suppressor cells in the ulcerative phase.
Direct and indirect immunofluorescence studies are not sensitive or specific diagnostic tests for RAS, and therefore should not be utilized except to rule out other oral mucosal diseases (e.g., pemphigus and pemphigoid).
The diagnosis of RAS is typically established from the history and clinical presentation. Usually, these conditions can be differentiated from RAS by the location of the lesion and/or the presence of an additional symptom. HSV infections may have similar-appearing lesions; however, primary HSV infections present with a diffuse gingival erythema and fever preceding oral mucosal vesicles and ulcers. Furthermore, recurrent HSV lesions are found primarily on attached keratinized mucosa, such as the hard palate or gingiva, Recurrent aphthous lesions can be differentiated from varicella-zoster virus infections (shingles) based on the clinical presentation (extraoral and intraoral distribution pattern) and other burning symptoms. Less common oral viral infections, such as herpangina and hand-foot-and-mouth disease, should also be included in the differential diagnosis of RAS when initial symptoms occur. Erythema multiforme presents with painful oral ulcers, but unlike RAS, erythema multiforme lesions occur on both attached and movable mucosa and usually involve crusting of the lips with skin macules and papules.
Goals of treatment Treatment of RAS has 4 major goals; (1) ulcer management (to promote healing and reduce duration), (2) pain management (to reduce morbidity and enhance function), (3) nutritional management (to ensure adequate food and fluid intake), and (4) disease control (to prevent recurrence or reduce frequency). The relative importance and priority of each goal depends on the severity of the condition.
Primary line of treatment
Topical gels, creams, and ointments. The primary treatment of RAS lesions utilizes topical anti-inflammatory agents. Strong topical corticosteroids when compounded with mucosal adherents (e.g., Orábase, Bristol-Myers Squibb; isobutyl cyanoacrylate or Iso-Dent, Ellman International) are effective despite limited contact time.,
Secondary line of treatment
For the patient whose symptoms are not relieved by the primary line of treatment or whose signs and symptoms warrant a more aggressive treatment modality, prednisone should be considered for both HIV-negative ,, and HIV-positive patients,,, Prednisone, an anti-inflammatory and an immunosuppressive agent, can be used in combination with topical gels and rinses.
Tertiary line of treatment
Thalidomide, an inhibitor of tumor necrosis, can be used. Factor-K, has been shown to be an effective treatment for severe RAS, despite the potential for significant side effects., Use of thalidomide in children has been documented with some success, but long-term effects have not been established.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
|1||Ship JA, Chavez EM, Doerr PA, Henson BS, Sarmadi M. Recurrent aphthous stomatitis. Quintessence Int 2000;31:95-112.|
|2||Ship JA. Recurrent aphthous stomatitis. An update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;81:141-7.|
|3||Miller MF, Ship II. A retrospective study of the prevalence and incidence of recurrent aphthous ulcers in a professional population, 1958-1971. Oral Surg Oral Med Oral Pathol 1977;43:532-7.|
|4||Miller MF, Garfunkel AA, Ram CA, Ship II. The inheritance of recurrent aphthous stomatitis. Observations on susceptibility. Oral Surg Oral Med Oral Pathol 1980;49:409-12.|
|5||Ship II. Epidemiologic aspects of recurrent aphthous ulcerations. Oral Surg Oral Med Oral Pathol 1972;33:400-6.|
|6||Kleinman DV, Swango PA, Pindborg JJ. Epidemiology of oral mucosal lesions in United States schoolchildren: 1986-87. Community Dent Oral Epidemiol 1994;22:243-53.|
|7||Field EA, Brookes V, Tyldesley WR. Recurrent aphthous ulceration in children – A review. Int J Paediatr Dent 1992;2:1-0.|
|8||Ship II. Inheritance of aphthous ulcers of the mouth. J Dent Res 1965;44:837-44.|
|9||Miller MF, Garfunkel AA, Ram C, Ship II. Inheritance patterns in recurrent aphthous ulcers: Twin and pedigree data. Oral Surg Oral Med Oral Pathol 1977;43:886-91.|
|10||Scully C, Porter S. Recurrent aphthous stomatitis: Current concepts of etiology, pathogenesis and management. J Oral Pathol Med 1989;18:21-7.|
|11||Ross R, Kitscher AH, Zegarelli EV, Pitt ID, Silvers H. Relationship of mechanical trauma to recurrent aphthous stomatitis. N Y State Dent J 1985;22:101-2.|
|12||Rennie JS, Reade PC, Hay KD, Scully C. Recurrent aphthous stomatitis. Br Dent J 1985;159:361-7.|
|13||Polanska B, Niemczuk M, Augustyniak D, Jankowski A. Plasma neutrophil elastase in children with recurrent aphthous stomatitis. Centr Eur J Immunol 2006;31:15-7.|
|14||Axéll T, Henricsson V. Association between recurrent aphthous ulcers and tobacco habits. Scand J Dent Res 1985;93:239-42.|
|15||Bittoun R. Recurrent aphthous ulcers and nicotine. Med J Aust 1991;154:471-2.|
|16||Natah SS, Konttinen YT, Enattah NS, Ashammakhi N, Sharkey KA, Häyrinen-Immonen R, et al. Recurrent aphthous ulcers today: A review of the growing knowledge. Int J Oral Maxillofac Surg 2004;33:221-34.|
|17||Scully C, Gorsky M, Lozada-Nur F. The diagnosis and management of recurrent aphthous stomatitis: A consensus approach. J Am Dent Assoc 2003;134:200-7.|
|18||Pedersen A. Recurrent aphthous ulceration: Virological and immunological aspects. APMIS 1993;101(Suppl 37):5-37.|
|19||Pedersen A, Hornsleth A. Recurrent aphthous ulceration: A possible clinical manifestation of reactivation of varicella zoster or cytomegalovirus infection. J Oral Pathol Med 1993;22:64-8.|
|20||Lehner T. Progress report: Oral ulceration and Behcet's syndrome. Gut 1977;18:491-511.|
|21||Porter SR, Scully C, Standen GR. Autoimmune neutropenia manifesting as recurrent oral ulceration. Oral Surg Oral Med Oral Pathol 1994;78:178-80.|
|22||Orme RL, Nordlund JJ, Barich L, Brown T. The MAGIC syndrome (mouth and genital ulcers with inflamed cartilage). Arch Dermatol 1990;126:940-4.|
|23||Grattan CE, Scully C. Oral ulceration: A diagnostic problem. Br Med J (Clin Res Ed) 1986;292:1093-4.|
|24||MacPhail LA, Greenspan D, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection. Diagnosis and treatment. Oral Surg Oral Med Oral Pathol 1992;73:283-8.|
|25||Veloso FT, Saleiro JV. Small-bowel changes in recurrent ulceration of the mouth. Hepatogastroenterology 1987;34:36-7.|
|26||Halme L, Meurman JH, Laine P, von Smitten K, Syrjänen S, Lindqvist C, et al. Oral findings in patients with active or inactive Crohn's disease. Oral Surg Oral Med Oral Pathol 1993;76:175-81.|
|27||McCartan BE, Sullivan A. The association of menstrual cycle, pregnancy, and menopause with recurrent oral aphthous stomatitis: A review and critique. Obstet Gynecol 1992;80:455-8.|
|28||Nolan A, McIntosh WB, Allam BF, Lamey PJ. Recurrent aphthous ulceration: Vitamin B1, B2 and B6 status and response to replacement therapy. J Oral Pathol Med 1991;20:389-91.|
|29||Porter SR, Kingsmill V, Scully C. Audit of diagnosis and investigations in patients with recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1993;76:449-52.|
|30||Volkov I, Rudoy I, Freud T, Sardal G, Naimer S, Peleg R, et al. Effectiveness of vitamin B12 in treating recurrent aphthous stomatitis: A randomized, double-blind, placebo-controlled trial. J Am Board Fam Med 2009;22:9-16.|
|31||Nolan A, Lamey PJ, Milligan KA, Forsyth A. Recurrent aphthous ulceration and food sensitivity. J Oral Pathol Med 1991;20:473-5.|
|32||Wardhana, Datau EA. Recurrent aphthous stomatitis caused by food allergy. Acta Med Indones 2010;42:236-40.|
|33||Ship II, Morris AL, Durocher RT, Burket WL. Recurrent aphthous ulcerations in a professional school student population. Oral Surg Oral Med Oral Pathol 1961;14:30-9.|
|34||Pedersen A. Psychologic stress and recurrent aphthous ulceration. J Oral Pathol Med 1989;18:119-22.|
|35||Huling LB, Baccaglini L, Choquette L, Feinn RS, Lalla RV. Effect of stressful life events on the onset and duration of recurrent aphthous stomatitis. J Oral Pathol Med 2012;41:149-52.|
|36||Keenan AV, Spivakovksy S. Stress associated with onset of recurrent aphthous stomatitis. Evid Based Dent 2013;14:25.|
|37||Landesberg R, Fallon M, Insel R. Alterations of T helper/inducer and T suppressor/inducer cells in patients with recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol 1990;69:205-8.|
|38||Burnett PR, Wray D. Lytic effects of serum and mononuclear leukocytes on oral epithelial cells in recurrent aphthous stomatitis. Clin Immunol Immunopathol 1985;34:197-204.|
|39||Greenspan JS, Gadol N, Olson JA, Talal N. Antibody-dependent cellular cytotoxicity in recurrent aphthous ulceration. Clin Exp Immunol 1981;44:603-10.|
|40||Lehner T. Immunoglobulin estimation of blood and saliva in human recurrent oral ulceration. Arch Oral Biol 1969;14:351-64.|
|41||Greenspan JS, Gadol N, Olson JA, Hoover CI, Jacobsen PL, Shillitoe EJ, et al. Lymphocyte function in recurrent aphthous ulceration. J Oral Pathol 1985;14:592-602.|
|42||Häyrinen-Immonen R, Malmström M, Nordström D, Sorsa T, Konttinen YT. Distribution of adhesion receptors in recurrent oral ulcers. J Oral Pathol Med 1992;21:199-202.|
|43||Pedersen A, Hougen HP, Kenrad B. T-lymphocyte subsets in oral mucosa of patients with recurrent aphthous ulceration. J Oral Pathol Med 1992;21:176-80.|
|44||Regezi JA, Macphail LA, Richards DW, Greenspan JS. A study of macrophages, macrophage-related cells, and endothelial adhesion molecules in recurrent aphthous ulcers in HIV-positive patients. J Dent Res 1993;72:1549-53.|
|45||Woo SB, Sonis ST. Recurrent aphthous ulcers: A review of diagnosis and treatment. J Am Dent Assoc 1996;127:1202-13.|
|46||Rogers RS 3rd. Recurrent aphthous stomatitis: Clinical characteristics and associated systemic disorders. Semin Cutan Med Surg 1997;16:278-83.|
|47||Porter SR, Scully C, Pedersen A. Recurrent aphthous stomatitis. Crit Rev Oral Biol Med 1998;9:306-21.|
|48||Sridhar T, Elumalai M, Karthika B. Recurrent Aphthous Stomatitis: A Review. Biomed Pharmacol J 2013;6:17-22.|
|49||Wray D, Vlagopoulos TP, Siraganian RP. Food allergens and basophil histamine release in recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1982;54:388-95.|
|50||Axéll T, Henricsson V. Association between recurrent aphthous ulcers and tobacco habits. Scand J Dent Res 1985;93:239-42.|
|51||Strassler HE. Recurrent aphthous stomatitis. Dent Learn 2012;1:1-9.|
|52||Pedersen A. Recurrent aphthous ulceration: Virological and immunological aspects. APMIS Suppl 1993;37:1-37.|
|53||Leena Sankari S, Masthan KM, Aravindha Babu N, Priyadharsini C. Biomed Pharmacol J 2013;6:33-9.|
|54||MacPhail LA, Greenspan JS. Oral ulceration in HIV infection: Investigation and pathogenesis. Oral Dis 1997;3 Suppl 1:S190-3.|
|55||Glick M, Muzyka BC, Lurie D, Salkin LM. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994;77:344-9.|
|56||Muzyka BC, Glick M. Major aphthous ulcers in patients with HIV disease. Oral Surg Oral Med Oral Pathol 1994;77:116-20.|
|57||MacPhail LA, Greenspan D, Feigal DW, Lennette ET, Greenspan JS. Recurrent aphthous ulcers in association with HIV infection. Description of ulcer types and analysis of T-lymphocyte subsets. Oral Surg Oral Med Oral Pathol 1991;71:678-83.|
|58||Porter SR, Scully C, Flint S. Hematologic status in recurrent aphthous stomatitis compared with other oral disease. Oral Surg Oral Med Oral Pathol 1988;66:41-4.|
|59||Rogers RS 3rd, Hutton KP. Screening for haematinic deficiencies in patients with recurrent aphthous stomatitis. Australas J Dermatol 1986;27:98-103.|
|60||Challacombe SI, Barkhan P, Lehner T. Haematological features and differentiation of reeurrcnt oral ulcération. Br Oral Sure 1977;15:37-45.|
|61||Field EA, Rotter E, Speechley JA, Tyldesley WR. Clinical and haematological assessment of children with recurrent aphthous ulceration. Br Dent J 1987;163:19-22.|
|62||Savage NW, Seymour GJ, Kruger BJ. T-lymphocyte subset changes in recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1985;60:175-81.|
|63||Mattingly G, Rodu B. Differential diagnosis of oral mueosal ulcérations. Compend Contin Educ Dent 1993;14:136, 138, 140.|
|64||Fenton SJ, Unkel JH. Viral infections of the oral mucosa in children: A clinical review. Pract Periodontics Aesthet Dent 1997;9:683-90.|
|65||Lozada F, Silverman S Jr. Erythema multiforme. Clinical characteristics and natural history in fifty patients. Oral Surg Oral Med Oral Pathol 1978;46:628-36.|
|66||Lozada-Nur F, Huang MZ, Zhou GA. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1991;71:283-7.|
|67||Plotkin GR, Patel BR, Shah VN. Behçet's syndrome complicated by cutaneous leukocytoclastic vasculitis. Response to prednisone and chlorambucil. Arch Intern Med 1985;145:1913-5.|
|68||Lozada F, Silverman S Jr., Migliorati C. Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases. J Am Dent Assoc 1984;109:269-70.|
|69||Vincent SD, Lilly GE. Clinical, historic, and therapeutic features of aphthous stomatitis. Literature review and open clinical trial employing steroids. Oral Surg Oral Med Oral Pathol 1992;74:79-86.|
|70||Reyes-Terán G, Ramírez-Amador V, De la Rosa E, González-Guevara M, Ponce de León S. Major recurrent oral ulcers in AIDS: Report of three cases. J Oral Pathol Med 1992;21:409-11.|
|71||de Asis ML, Bernstein LJ, Schliozberg J. Treatment of resistant oral aphthous ulcers in children with acquired immunodeficiency syndrome. J Pediatr 1995;127:663-5.|
|72||Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336:1487-93.|
|73||Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985;12(1 Pt l):85-90.|
|74||Menni S, Imondi D, Brancaleone W, Croci S. Recurrent giant aphthous ulcers in a child: Protracted treatment with thalidomide. Pediatr Dermatol 1993;10:283-5.|